ReviewSaudi medical journal2015
Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma.
Review in Saudi medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies.Frontiers in oncology · 2024Review
- Risk factor and prediction model development for severe radiation-induced oral mucositis in head and neck tumors.Future oncology (London, England) · 2024Article
- E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers.Frontiers in cell and developmental biology · 2023Review
- Pathogenesis and therapeutic implications of EBV-associated epithelial cancers.Frontiers in oncology · 2023Review
- Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.Translational oncology · 2022Review
- Ang2-Targeted Combination Therapy for Cancer Treatment.Frontiers in immunology · 2022Review
- Exosomal LBH inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating VEGFA signaling.International journal of biological sciences · 2022Article
- CircRNA ZNF609 promotes angiogenesis in nasopharyngeal carcinoma by regulating miR-145/STMN1 axis.The Kaohsiung journal of medical sciences · 2021Article
- miR-144 delivered by nasopharyngeal carcinoma-derived EVs stimulates angiogenesis through the FBXW7/HIF-1α/VEGF-A axis.Molecular therapy. Nucleic acids · 2021Article
- Inhibition of the Numb/Notch signaling pathway increases radiation sensitivity in human nasopharyngeal carcinoma cells.The Kaohsiung journal of medical sciences · 2019Article
- Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report.Medicine · 2019Article
- Overexpression of ERBB3 promotes proliferation, migration, and angiogenesis in nasopharyngeal carcinoma.International journal of clinical and experimental pathology · 2019Article
- Contrast-enhanced Ultrasound in evaluating of angiogenesis and tumor staging of nasopharyngeal carcinoma in nude mice.PloS one · 2019Article
- Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.Oncology letters · 2018Review
- Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma.Oncology letters · 2018Article
- Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation therapy is the primary treatment in nasopharyngeal carcinoma (NPC), and the effect of radiation therapy is strongly related to the oxygen content of cancer cells. That means, it is imperative to balance the interactions between radiotherapy and anti-angiogenesis therapy when giving combination therapy to improve clinical outcomes. The complicated mechanisms between antiangiogenic agents and radiation involve many interactions between the cancer cells, vasculature, and cancer stroma. The proliferation and metastasis of cancer depends on angiogenesis, while rapid growth of cancers will cause hypoxia, which contributes to radioresistance. Antiangiogenic agents can modulate the cancer blood flow and oxygenation through target cancer vasculature, leading to increased radiosensitivity. This study discusses the mechanisms of the synergistic effect of the antiangiogenic therapy with radiation therapy in metastatic NPC, and reviews the data supporting this strategy as a promising treatment for metastatic NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.